Table 1.
Animals Used in the Study.
| Tissue Sections
|
||||||||
|---|---|---|---|---|---|---|---|---|
| Animal ID | Survival (dpi) | SIV/AIDS | AIDS Defining Criteria | Carotid Artery | Left Ventricle | Treatment | CD8 Depletion | |
| Group 1 | 373–03 | NA | SIV− | – | N | Y | – | NA |
| 257–00 | NA | SIV− | – | N | Y | – | NA | |
| 417–08 | NA | SIV− | – | N | Y | – | NA | |
| 454–08 | NA | SIV− | – | N | Y | – | NA | |
| 96–10 | NA | SIV− | – | N | Y | – | NA | |
| 428–08 | NA | SIV− | – | N | Y | – | NA | |
|
| ||||||||
| Group 2 | 5035 | 49 | SIV+ | SIVE, CMV pneumonia | N | Y | Placebo | P |
| 5038 | 49 | SIV+ | SIVE, CMV pneumonia | N | Y | Placebo | P | |
| 5041 | 49 | SIV+, AIDS | CMV pneumonia | N | Y | MGBG | P | |
| 5042 | 49 | SIV+, No AIDS | – | N | Y | MGBG | P | |
|
| ||||||||
| Group 3 | 299–10 | 63 | SIV+, AIDS | SIV pneumonia, CMV pneumonia | Y | Y | Placebo | P |
| 264–10 | 63 | SIV+, AIDS | CMV brain, CMV lung | Y | Y | MGBG | P | |
| 186–10 | 63 | SIV+, No AIDS | – | Y | Y | MGBG | P | |
|
| ||||||||
| Group 4 | 296–10 | 70 | SIV+ | SIV giant cell lung, P.carinii | Y | Y | Placebo | P |
| 291–10 | 70 | SIV+, No AIDS | – | Y | Y | MGBG | R | |
| 273–10 | 70 | SIV+, No AIDS | – | Y | Y | MGBG | P | |
|
| ||||||||
| Group 5 | 291–09 | 77 | SIV+ | SIVE | Y | Y | Placebo | R |
| 275–10 | 77 | SIV+, AIDS | CMV pneumonia, adenovirus in jejunum | Y | Y | MGBG | P | |
| 328–10 | 77 | SIV+ No AIDS | – | Y | Y | MGBG | P | |
|
| ||||||||
| Group 6 | 326–10 | 83 | SIV+, AIDS | Lymphoma | Y | Y | Placebo | P |
| 201–10 | 83 | SIV+, No AIDS | – | Y | Y | MGBG | P | |
| 272–10 | 83 | SIV+, AIDS | Y | Y | MGBG | P | ||
|
| ||||||||
| Group 7 | 434–10 | 84 | SIV+, AIDS | P. carinii in lung | Y | Y | Placebo | R |
| 262–09 | 84 | SIV+, No AIDS | – | Y | Y | Placebo | R | |
| 272–09 | 84 | SIV+, No AIDS | – | Y | Y | MGBG | R | |
Twenty-five animals were used in this study to examine the effects of MGBG treatment on cardiovascular inflammation. Six animals were uninfected (group 1). The remaining 19 animals (groups 2–7) were either treated daily with MGBG or given a placebo control. Animals were grouped and sacrificed at the indicated days post infection (dpi) when placebo controls developed AIDS or at the end of the study (84 dpi). AIDS was assessed based on the presence of SIVE, (SIV-encephalitis) or the following opportunistic infections (OIs) Cytomegalovirus (CMV), pneumocystis carinii (P. carinii), and lymphoma. For sections of carotid artery and left ventricle, N indicates no section was taken from the indicated animal, Y indicates that a tissue section was taken. CD8+ T-lymphocyte were either persistently (P) depleted from SIV-infected animals or they returned ®. Persistently depleted animals are defined as animals where numbers of CD8+ T-lymphocytes in circulation at necropsy are less than 75% of the number of CD8+ T-lymphocytes at 0dpi. Nine of 11 (81.8%) MGBG treated and 5 of 8 placebo control (62.5%) animals in this study were persistently depleted.